65,437 trials
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.31; -1.46; -1.29 percentage of glycosylated haemoglobin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (%) — -1.23; -1.42 percentage change in HbA1c
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 107.3; 95.5; 424.5; 471.0 ng/mL
Thrombocythemia, Essential
Primary: Percentage of Participants With At Least One Pre-Defined Event (PDE), Deaths, Pregnancies — 1.0; 0.0; 1.5; 0.7 percentage of participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.09; -0.93 percentage of glycosylated haemoglobin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.26; -1.28; -1.46; -1.49 percentage of glycosylated haemoglobin
Overweight
Primary: Weight Change (in kg.) After Each Intervention — -0.39; 0.02 kg weight change
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) — 77.1; 83.8 Percentage of participants
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26 — 31.7; 88.4 Percentage of Participants
Parkinson Disease
Primary: Cmax - Maximum Plasma Concentration — 985; 1245; 1200; 944 ng/mL
Obstructive Sleep Apnea
Primary: Mesenteric Fat Thickness — 0.96; 0.94 cm
Diabetes · Diabetes Mellitus, Type 1
Primary: Rate of Major and Minor Hypoglycaemic Episodes — 0; 0; 62.97; 80.84 Episodes /year of patient exposure
Shoulder Pain
Primary: Visual Analog Scale Pain Scores — 1.3; 1.5 units on a scale
Diabetes · Diabetes Mellitus, Type 1
Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment — -0.73; -0.65 percentage of glycosylated haemoglobin
Post-Traumatic Stress Disorder
Primary: Clinician-Administered PTSD Scale (CAPS) — 68.9; 72.1; 68.9; 39.8 units on a scale